These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
429 related articles for article (PubMed ID: 30871458)
1. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA. Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458 [TBL] [Abstract][Full Text] [Related]
2. Mining FDA drug labels using an unsupervised learning technique--topic modeling. Bisgin H; Liu Z; Fang H; Xu X; Tong W BMC Bioinformatics; 2011 Oct; 12 Suppl 10(Suppl 10):S11. PubMed ID: 22166012 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology. Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093 [TBL] [Abstract][Full Text] [Related]
4. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database. Castillon G; Salvo F; Moride Y Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742 [TBL] [Abstract][Full Text] [Related]
5. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese. Inácio P; Airaksinen M; Cavaco A Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069 [TBL] [Abstract][Full Text] [Related]
6. Information on adverse drug reactions-Proof of principle for a structured database that allows customization of drug information. Kusch MKP; Zien A; Hachenberg C; Haefeli WE; Seidling HM Int J Med Inform; 2020 Jan; 133():103970. PubMed ID: 31704490 [TBL] [Abstract][Full Text] [Related]
7. From narrative descriptions to MedDRA: automagically encoding adverse drug reactions. Combi C; Zorzi M; Pozzani G; Moretti U; Arzenton E J Biomed Inform; 2018 Aug; 84():184-199. PubMed ID: 29981491 [TBL] [Abstract][Full Text] [Related]
8. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Bousquet C; Lagier G; Lillo-Le Louët A; Le Beller C; Venot A; Jaulent MC Drug Saf; 2005; 28(1):19-34. PubMed ID: 15649103 [TBL] [Abstract][Full Text] [Related]
9. A dataset of 200 structured product labels annotated for adverse drug reactions. Demner-Fushman D; Shooshan SE; Rodriguez L; Aronson AR; Lang F; Rogers W; Roberts K; Tonning J Sci Data; 2018 Jan; 5():180001. PubMed ID: 29381145 [TBL] [Abstract][Full Text] [Related]
10. Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis. Lavertu A; Hamamsy T; Altman RB J Med Internet Res; 2021 Oct; 23(10):e27714. PubMed ID: 34673524 [TBL] [Abstract][Full Text] [Related]
11. Ontology-based literature mining and class effect analysis of adverse drug reactions associated with neuropathy-inducing drugs. Hur J; Özgür A; He Y J Biomed Semantics; 2018 Jun; 9(1):17. PubMed ID: 29880031 [TBL] [Abstract][Full Text] [Related]
12. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Brown EG Drug Saf; 2003; 26(3):145-58. PubMed ID: 12580645 [TBL] [Abstract][Full Text] [Related]
13. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database. Beninger P; Murray M Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758 [TBL] [Abstract][Full Text] [Related]
15. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Brown EG Drug Saf; 2002; 25(6):445-52. PubMed ID: 12071782 [TBL] [Abstract][Full Text] [Related]
16. MedDRA Labeling Groupings to Improve Safety Communication in Product Labels. Große-Michaelis I; Proestel S; Rao RM; Dillman BS; Bader-Weder S; Macdonald L; Gregory W Ther Innov Regul Sci; 2023 Jan; 57(1):1-6. PubMed ID: 35939205 [TBL] [Abstract][Full Text] [Related]
17. Machine learning-based identification and rule-based normalization of adverse drug reactions in drug labels. Tiftikci M; Özgür A; He Y; Hur J BMC Bioinformatics; 2019 Dec; 20(Suppl 21):707. PubMed ID: 31865904 [TBL] [Abstract][Full Text] [Related]
18. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs. Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866 [TBL] [Abstract][Full Text] [Related]
19. Supervised signal detection for adverse drug reactions in medication dispensing data. Hoang T; Liu J; Roughead E; Pratt N; Li J Comput Methods Programs Biomed; 2018 Jul; 161():25-38. PubMed ID: 29852965 [TBL] [Abstract][Full Text] [Related]
20. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. Cornelius VR; Liu K; Peacock J; Sauzet O BMJ Open; 2016 Mar; 6(3):e010599. PubMed ID: 26996819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]